Signal Transduction and Targeted Therapy: review time and acceptance speed
ISSN 2059-3635 · ISSN 2095-9907 · Springer Nature · Medicine
Half of the articles Signal Transduction and Targeted Therapy accepted in 2025 were accepted within 177 days of submission (n = 402); the middle half took 124–228 days.
Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026
How long does Signal Transduction and Targeted Therapy take to accept a paper?
| Year | Articles (n) | 25th pct | Median | 75th pct | 90th pct | Accepted <14 days | Have a revised date |
|---|---|---|---|---|---|---|---|
| 2025 | 402 | 124 | 177 | 228 | 294 | 2.2% | 98% |
| 2024 | 345 | 72 | 144 | 203 | 266 | 2.3% | 100% |
| 2023 | 309 | 99 | 155 | 211 | 277 | 0.3% | 99% |
| 2022 | 235 | 80 | 118 | 164 | 218 | 0.0% | 100% |
| 2021 | 214 | 77 | 132 | 174 | 231 | 1.4% | 97% |
| 2020 | 195 | 61 | 95 | 135 | — | 4.6% | 96% |
- 2026: not shown yet — a year is reported once late-indexed articles have arrived (at least 180 days after it ends).
Research articles vs reviews (2025)
| Type | n | 25th pct | Median | 75th pct |
|---|---|---|---|---|
| Research articles | 327 | 104 | 165 | 221 |
| Reviews | 75 | 173 | 218 | 271 |
Distribution in 2025
Show as a table
| Days | Articles | Share |
|---|---|---|
| 0–29 | 35 | 8.7% |
| 30–59 | 43 | 10.7% |
| 60–89 | 3 | 0.7% |
| 90–119 | 18 | 4.5% |
| 120–149 | 51 | 12.7% |
| 150–179 | 54 | 13.4% |
| 180–209 | 65 | 16.2% |
| 210–239 | 47 | 11.7% |
| 240–269 | 29 | 7.2% |
| 270–299 | 20 | 5.0% |
| 300–329 | 16 | 4.0% |
| 330–359 | 4 | 1.0% |
| 360+ | 17 | 4.2% |
From acceptance to online publication
After acceptance, half of the 2025 articles appeared online within 35 days (middle half 28–42 days, n = 402).
From submission to online publication, the median was 213 days (middle half 152–277 days, n = 402).
Read these numbers carefully
- These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
- Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
- Invited articles and special issues can move faster than regular submissions.
Open access status and publishing fees
Open access (listed in DOAJ). Listed APC: $4,170 (DOAJ).
Institutions reported paying a median of about $3,146 per article (2023–2025, 10 reported payments in OpenAPC; converted from euros at yearly ECB average rates).
Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.
Integrity and indexing signals
Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.
| Listed in DOAJ | Yes (DOAJ record) |
|---|---|
| Articles indexed for MEDLINE in 2025 | Yes |
| Retractions | 0 retracted articles among 1,500 added to PubMed in 2021–2025 (0.00 per 1,000), per the Retraction Watch Database. |
| Accepted within 14 days of submission | 2.2% of 2025 articles |
| Publication volume | 393 articles added to PubMed in 2025 (+21% vs 2024). |
Topics and scope
- SARS-CoV-2 and COVID-19 Research (11% of indexed topics)
- COVID-19 Clinical Research Studies (7% of indexed topics)
- Cancer Immunotherapy and Biomarkers (6% of indexed topics)
- RNA modifications and cancer (6% of indexed topics)
- Immune Cell Function and Interaction (5% of indexed topics)
- CAR-T cell therapy research (5% of indexed topics)
Medicine journalsBiochemistry, Genetics and Molecular Biology journals
Similar journals — faster or cheaper, side by side
Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2025 figures are compared with the 2025 median of Signal Transduction and Targeted Therapy, 177 days.
| Paid APC median | DOAJ | MEDLINE | |||
|---|---|---|---|---|---|
| MedComm | 256 (2025, n = 464) | $3,850 | — | Yes | No |
| Molecular Biomedicine | 212 (2025, n = 140) | $2,990 | — | Yes | Yes |
| Cell Reports Medicine | 232 (2025, n = 456) | $5,790 | $5,240 (23 payments) | Yes | Yes |
| Cell Discovery | 177 (2025, n = 67) | $3,690 | — | Yes | No |
| Frontiers of Medicine | 114 (2025, n = 58) | ≈$2,390 | — | No | Yes |
| Clinical and Translational Medicine | 116 (2025, n = 313) | $3,640 | $3,103 (6 payments) | Yes | Yes |
| Med | 98 (2025, n = 156) | ≈$9,350 | — | No | Yes |
| iScience | 182 (2025, n = 2,505) | $3,240 | $3,046 (266 payments) | Yes | No |
| EBioMedicine | 161 (2025, n = 503) | $6,810 | $4,922 (46 payments) | Yes | Yes |
| Clinical & Translational Immunology | 147 (2025, n = 52) | $3,380 | — | Yes | No |
No journals match these filters.
Frequently asked questions
How long does Signal Transduction and Targeted Therapy take to accept a paper?
Half of the articles Signal Transduction and Targeted Therapy accepted in 2025 were accepted within 177 days of submission (n = 402); the middle half took 124–228 days. Based on dates in PubMed for accepted articles only.
How long after acceptance are Signal Transduction and Targeted Therapy articles published online?
Half of the articles accepted in 2025 appeared online within 35 days of acceptance (n = 402).
Does Signal Transduction and Targeted Therapy charge an article processing charge (APC)?
Listed APC: $4,170 (DOAJ).
Sources and method
Journal identity: ISSN-L 2059-3635; NLM ID 101676423; OpenAlex record. Speed figures use 402 articles accepted in 2025 with valid dates; excluded records for that year: none.
Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.